Provided by Tiger Trade Technology Pte. Ltd.

Invivyd, Inc.

1.74
-0.0600-3.33%
Post-market: 1.770.0300+1.72%19:26 EDT
Volume:2.68M
Turnover:4.80M
Market Cap:490.68M
PE:-5.71
High:1.86
Open:1.82
Low:1.72
Close:1.80
52wk High:3.07
52wk Low:0.4600
Shares:282.00M
Float Shares:204.00M
Volume Ratio:1.07
T/O Rate:1.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3048
EPS(LYR):-0.3048
ROE:-33.96%
ROA:-17.09%
PB:2.03
PE(LYR):-5.71

Loading ...

BUZZ-Invivyd rises after team-up with Olympic skier Lindsey Vonn

Reuters
·
Jan 22

Invivyd announces partnership with ski champion Lindsey Vonn

TIPRANKS
·
Jan 22

Invivyd Partners with Lindsey Vonn to Promote Antibody Education

Reuters
·
Jan 22

Invivyd Announces Partnership With World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention

THOMSON REUTERS
·
Jan 22

Invivyd to Launch Mid-Stage Trial for Investigational Antibody on Long COVID

MT Newswires Live
·
Jan 20

Invivyd and Spear Study Group Announce Plan for Phase 2 Study of Vyd2311 for Treatment of Long Covid and Covid Vaccine-Injured Individuals to Commence Mid-2026

THOMSON REUTERS
·
Jan 20

Invivyd, SPEAR Study Group plan to initiate Phase 2 trial of VYD2311

TIPRANKS
·
Jan 20

Invivyd Reports Preliminary Q4 Revenue and Launches Phase 3 DECLARATION Trial

Reuters
·
Jan 08

Invivyd Inc - Prelim Q4 2025 Pemgarda Revenue of $17.2 Mln

THOMSON REUTERS
·
Jan 08

Press Release: Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

Dow Jones
·
Jan 08

Invivyd Price Target Maintained With a $10.00/Share by BTIG

Dow Jones
·
Dec 24, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Invivyd, US natgas companies, New Era Energy

Reuters
·
Dec 24, 2025

Invivyd Shares Gain 3.8% After Co Starts Late-Stage Trial for Covid Prevention Antibody

THOMSON REUTERS
·
Dec 23, 2025

Invivyd Shares up 2% Premarket After Co Starts Late-Stage Trial for Covid Prevention Antibody

THOMSON REUTERS
·
Dec 23, 2025

BUZZ-Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody

Reuters
·
Dec 23, 2025

Invivyd Inc - FDA Grants Fast Track Designation for Invivyd's Vyd2311

THOMSON REUTERS
·
Dec 23, 2025

FDA Grants Fast Track Designation to Invivyd's COVID Prevention Antibody VYD2311

Reuters
·
Dec 23, 2025

Invivyd Launches Phase 3 Trial of VYD2311 Antibody for COVID Prevention

Reuters
·
Dec 23, 2025

Invivyd Inc - Top-Line Data Expected Mid-2026

THOMSON REUTERS
·
Dec 23, 2025

Invivyd Inc - Trial to Enroll 1770 Participants for Covid Incidence Reduction

THOMSON REUTERS
·
Dec 23, 2025